OrbiMed, a global healthcare investment firm, raised more than $4.3 billion in commitments for its latest private investment funds, including OrbiMed Private Investments IX, OrbiMed Asia Partners V and OrbiMed Royalty & Credit Opportunities IV.
Investors in these new vehicles include a broad range of medical institutions, university endowments, foundations, pension funds, sovereign wealth funds and family offices.
Consistent with their predecessors, these new funds enable the firm to invest globally, from seed stage for startups incubated by OrbiMed through growth capital opportunities. The firm works closely with its portfolio companies to provide tailored financing solutions, which can include equity, credit and royalty-based financing.
OrbiMed focuses on innovative and growth-oriented opportunities across healthcare sub-sectors, including biopharmaceuticals, medical devices, diagnostics and technology-enabled healthcare services.
The firm is led by its 21 partners, with a team of over 130 professionals that contribute diverse, complementary skills across company incubation, strategy, operations and finance.
The team is based in New York City; London; San Francisco; Shanghai; Hong Kong; Mumbai, India; Herzliya, Israel; and other key global markets.